Cambridge, Mass., May 7, 2026 – GentiBio, a clinical-stage biotechnology company advancing a pipeline of engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced it will present 9 abstracts including 5 oral presentations at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11–15.
GentiBio is currently enrolling patients in its Phase 1 POLARIS clinical trial evaluating GNTI-122 in individuals with newly diagnosed Type 1 diabetes. More information about the trial can be found here: polarisstudy.com. Presentations on GNTI-122 will include information on manufacturability, clinical development, biomarker strategy, and an oral presentation on the comprehensive genotox package.
In addition, GentiBio will present data across its platform and pipeline. These include advances in tissue-targeted and allogeneic therapies, immune evasion strategies to enhance persistence, and the development of next-generation programs such as GNTI‑350 and GNTI‑932. These presentations highlight the versatility of GentiBio’s platform to generate, allogeneic, durable, targeted engineered Treg therapies for a range of indications.
In addition, GentiBio will present data across its platform and pipeline. These include advances in tissue-targeted and allogeneic therapies, immune evasion strategies to enhance persistence, and the development of next-generation programs such as GNTI‑350 and GNTI‑932. These presentations highlight the versatility of GentiBio’s platform to generate, allogeneic, durable, targeted engineered Treg therapies for a range of indications.
These findings represent an important step in translating engineered Treg therapies from research to clinical use and underscore the company’s progress toward delivering novel cell therapies for the treatment of autoimmune and inflammatory diseases.
Posters
Available from 9 am, reception at 5:00 pm (respective day). Connect with authors via the conference app for questions or to schedule discussions.
Title: ST2 enforces a ‘repair-ready’ T regulatory cell phenotype that homes to and ameliorates neuroinflammation (ID 1483)
Presenter: Nathan Zammit
Date: Tuesday, May 12, 2026
Title: Development and Characterization of GNTI-350, a CD19-Targeted Allogeneic Engineered Regulatory T Cell Therapy (ID 2260)
Presenter: Christopher Moore
Date: Wednesday, May 13, 2026
Title: Early -phase clinical evaluation of GNTI-122, an engineered regulatory T cell therapy, in the POLARIS study for recent-onset type 1 diabetes (ID 3366)
Presenter: Gene Uenishi
Date: Thursday, May 14, 2026
Title: Clinical biomarker strategy enabling first-in-human evaluation of the engineered Treg therapy GNTI-122 in type 1 diabetes (ID 3369)
Presenter: Dalia Gaddis
Date: Thursday, May 14, 2026
Seminars
Title: Modular Engineering of hypoimmune Regulatory T cells enables off-the-shelf therapeutics for autoimmune and inflammatory diseases.
Presenter: Payam Zarin
Session: Novel T-cell and myeloid strategies
Date/Time: Tuesday, May 12 at 3:45 pm ET
Location: MCEC Room 206AB (Level 2)
Title: Allogeneic murine tissue engineered T regulatory cells improve disease outcome in models of acute lung injury and pulmonary fibrosis in mice
Presenter: Maegan Hoover
Session: Transforming immune modulation with gene-modified regulatory T-cells
Date/Time: Thursday, May 14 at 8:45 am ET
Location: Westin Seaport Grand Ballroom AB (Concourse Level)
Title: GNTI 932: A Targeted and Hypoimmune Allogeneic Engineered Treg Therapy for Inflammatory Bowel Disease
Presenter: Martina Sassone-Corsi
Session: Transforming immune modulation with gene-modified regulatory T-cells
Date/Time: Thursday, May 14 at 9:00 am ET
Location: Westin Seaport Grand Ballroom AB (Concourse Level)
Title: Comprehensive genotoxicity evaluation of GNTI-122, an engineered Treg therapy for type 1 diabetes
Presenter: Marko Repic
Session: Understanding on- and off-target activity in gene therapy
Date/Time: Thursday, May 14 at 4:15 pm ET
Location: MCEC Room 205ABC (Level 2)
Title: Synthetic NKG2A engager enables long-term persistence of allogeneic human leukocyte antigen knockout engineered regulatory T cells
Presenter: Christopher Moore
Session: Rewriting immunity: Innovations advancing the safety and efficacy of engineered therapeutics
Date/Time: Thursday, May 14 at 4:15 pm ET
Location: MCEC Room 205ABC (Level 2)
The GentiBio team will be available at the meeting to connect with clinicians, researchers, and others in the community to discuss GentiBio’s progress in advancing engineered Treg therapies, including the ongoing POLARIS clinical trial.
About GNTI-122 and EngTreg Therapy
GNTI-122 is a novel, single-treatment, autologous engineered regulatory T cell (EngTreg) investigational therapy designed to restore immune tolerance by selectively suppressing autoreactive immune responses that drive type 1 diabetes. GNTI-122 cells are designed to migrate to the pancreas and associated lymphoid tissues and remain there to stably mitigate the immune response, preserving endogenous insulin production. GentiBio’s EngTreg platform builds on foundational discoveries in Treg biology, recognized by the 2025 Nobel Prize in Physiology or Medicine, and is designed to deliver targeted, durable immunomodulation with the goal of addressing the root cause of autoimmune disease.
About the POLARIS Study
Phase 1, Single Dose, Open-LAbel Study of GNTI-122 in Adults with Recently dIagnoSed Type 1 Diabetes (T1D) [POLARIS (NCT06919354)] is a clinical trial enrolling adults aged 18–55 years within 180 days of T1D diagnosis. The study evaluates the safety and tolerability of escalating doses of GNTI-122 and includes secondary and exploratory assessments of pharmacodynamic activity and clinical biomarkers, including measures of beta cell function. Participants are followed for up to 78 weeks. For more information, visit polarisstudy.com or ClinicalTrials.gov.
About GentiBio
GentiBio is a biotechnology company developing engineered regulatory T cell (EngTreg) therapies to restore immune tolerance and transform the treatment of autoimmune and inflammatory diseases. GentiBio’s EngTregs harness the underlying power of Tregs and are engineered for precision, durability, and scalable manufacture. GentiBio seeks to deliver disease modifying, and potentially curative, therapies for patients with significant unmet need. Learn more at gentibio.com.
Contact
Media email: Hatem.Heikal@gentibio.com